INT80124

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1998
Last Reported 2011
Negated 2
Speculated 9
Reported most in Body
Documents 450
Total Number 459
Disease Relevance 311.19
Pain Relevance 44.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (VEGFA) growth (VEGFA) extracellular region (VEGFA)
proteinaceous extracellular matrix (VEGFA) cytoplasm (VEGFA)
Anatomy Link Frequency
endothelial cells 14
plasma 12
vasculature 11
lung 10
fibroblast 6
VEGFA (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 1061 100.00 Very High Very High Very High
metalloproteinase 338 100.00 Very High Very High Very High
palliative 187 100.00 Very High Very High Very High
Inflammatory mediators 75 100.00 Very High Very High Very High
Kinase C 59 100.00 Very High Very High Very High
dexamethasone 748 99.84 Very High Very High Very High
cINOD 265 99.80 Very High Very High Very High
aspirin 41 99.80 Very High Very High Very High
Inflammation 2322 99.72 Very High Very High Very High
ischemia 279 99.60 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cancer 10888 100.00 Very High Very High Very High
Disease 2825 100.00 Very High Very High Very High
INFLAMMATION 2656 100.00 Very High Very High Very High
Pressure And Volume Under Development 526 100.00 Very High Very High Very High
Fibromyalgia 42 100.00 Very High Very High Very High
Repression 41 100.00 Very High Very High Very High
Sensorineural Hearing Loss 16 100.00 Very High Very High Very High
Pathologic Neovascularization 84 99.92 Very High Very High Very High
Diabetes Mellitus 2081 99.90 Very High Very High Very High
Apoptosis 1474 99.90 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of VEGF can be achieved by blocking its receptors or the molecule itself.
Negative_regulation (Inhibition) of VEGF
1) Confidence 0.58 Published 2007 Journal Indian Journal of Ophthalmology Section Body Doc Link PMC2635972 Disease Relevance 0.42 Pain Relevance 0
This method was frequency used in several studies.[2122] In this study, although VEGF level was reduced in urine after BCG therapy, but this change was not statistically significant.
Negative_regulation (reduced) of VEGF in urine
2) Confidence 0.57 Published 2010 Journal Urology Annals Section Body Doc Link PMC2955232 Disease Relevance 1.24 Pain Relevance 0
VEGF inhibition has also been associated with arterial thrombotic events.
Negative_regulation (inhibition) of VEGF
3) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643117 Disease Relevance 1.00 Pain Relevance 0.18
Further studies regarding the potential tonic arterioprotective effects of VEGF and the potential role of VEGF inhibition in the pathophysiology of takotsubo cardiomyopathy are warranted.



Negative_regulation (inhibition) of VEGF associated with takotsubo cardiomyopathy
4) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643117 Disease Relevance 0.68 Pain Relevance 0
These findings suggest that inhibition of VEGF is associated with the transition from compensatory hypertrophy to overt failure (Izumiya et al 2006).
Negative_regulation (inhibition) of VEGF associated with hypertrophy
5) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643117 Disease Relevance 1.05 Pain Relevance 0.18
The exact nature of the relationship between exposure to bevacizumab, the subsequent VEGF inhibition, and takotsubo cardiomyopathy remains to be seen.
Negative_regulation (inhibition) of VEGF associated with takotsubo cardiomyopathy
6) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643117 Disease Relevance 0.72 Pain Relevance 0
Sunitinib, sorafenib, axitinib, and pazopanib are oral tyrosine kinase inhibitors (TKIs) of multiple receptors (R), including VEGFRs and PDGFRs.
Negative_regulation (inhibitors) of VEGF
7) Confidence 0.57 Published 2010 Journal Target Oncol Section Body Doc Link PMC2929340 Disease Relevance 0.64 Pain Relevance 0.04
The mechanism of action of the mTOR inhibitors is quite distinct from those of drugs inhibiting VEGFR/PDGFR.
Negative_regulation (inhibiting) of VEGF
8) Confidence 0.57 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.76 Pain Relevance 0
Especially, as blocking VEGF activity has been shown to sensitize the vasculature and improve the delivery of cytotoxic drugs to tumor and endothelial cells.
Negative_regulation (blocking) of VEGF in endothelial cells associated with cancer
9) Confidence 0.56 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.80 Pain Relevance 0
Because the inhibition of VEGF is a non-curative approach, it is not foreseeable at any time in the future that patients will be able to definitely terminate the treatment.
Negative_regulation (inhibition) of VEGF
10) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698673 Disease Relevance 0.51 Pain Relevance 0
Therefore, the decrease in VEGF may be an important part of the mechanism how IL-6 receptor inhibition with tocilizumab exerts its therapeutic efficacy in RA.
Negative_regulation (decrease) of VEGF associated with rheumatoid arthritis
11) Confidence 0.53 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638601 Disease Relevance 0.79 Pain Relevance 0.40
Since serum VEGF levels correlate with disease activity scores and radiographic progression in RA patients [16, 25], the dramatic decrease in VEGF also underlines the efficacy of tocilizumab.
Negative_regulation (decrease) of VEGF associated with rheumatoid arthritis and disease
12) Confidence 0.53 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638601 Disease Relevance 0.95 Pain Relevance 0.34
After thalidomide treatment, plasma vascular endothelial growth factor (VEGF) level was significantly reduced in responders (P = 0.025), but not in non-responders (P = 0.37).
Negative_regulation (reduced) of VEGF in plasma
13) Confidence 0.52 Published 2002 Journal Jpn. J. Cancer Res. Section Abstract Doc Link 12359057 Disease Relevance 0.71 Pain Relevance 0.10
After thalidomide treatment, plasma vascular endothelial growth factor (VEGF) level was significantly reduced in responders (P = 0.025), but not in non-responders (P = 0.37).
Negative_regulation (reduced) of vascular endothelial growth factor in plasma
14) Confidence 0.52 Published 2002 Journal Jpn. J. Cancer Res. Section Abstract Doc Link 12359057 Disease Relevance 0.82 Pain Relevance 0.10
Reduction of plasma VEGF level might be an important indicator for anti-myeloma effect of thalidomide.
Negative_regulation (Reduction) of VEGF in plasma
15) Confidence 0.52 Published 2002 Journal Jpn. J. Cancer Res. Section Abstract Doc Link 12359057 Disease Relevance 0.67 Pain Relevance 0.10
Marked decrease of plasma VEGF after implantation of autologous bone marrow mononuclear cells in a patient with critical limb ischemia--a case report.
Negative_regulation (decrease) of plasma VEGF in limb associated with ischemia
16) Confidence 0.51 Published 2006 Journal Angiology Section Title Doc Link 16518534 Disease Relevance 0.34 Pain Relevance 0.21
VEGF is not only involved in the regulation of neovascularization, it also has been proven in animal studies that if VEGF were suppressed at the level of mRNA or protein, corneal neovascularization was also decreased [2,14,27].
Negative_regulation (suppressed) of VEGF associated with corneal neovascularization
17) Confidence 0.50 Published 2010 Journal Korean Journal of Ophthalmology : KJO Section Body Doc Link PMC2916105 Disease Relevance 0.50 Pain Relevance 0.03
In both the groups, urine VEGF was reduced after BCG therapy; however, this reduction was more in high grade group.
Negative_regulation (reduced) of urine VEGF in urine
18) Confidence 0.50 Published 2010 Journal Urology Annals Section Body Doc Link PMC2955232 Disease Relevance 0.58 Pain Relevance 0.06
Serum VEGF level was reduced in high grade group but not statistically significant difference was observed.
Negative_regulation (reduced) of Serum VEGF
19) Confidence 0.50 Published 2010 Journal Urology Annals Section Body Doc Link PMC2955232 Disease Relevance 0.57 Pain Relevance 0.06
Our data indeed support the view that a decrease of VEGF serum levels is a good indicator of response in TNF-?
Negative_regulation (decrease) of VEGF
20) Confidence 0.48 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592815 Disease Relevance 0.58 Pain Relevance 0.95

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox